IsoRay, Inc., a Richland-based developer of therapies for prostate and other cancers, has announced the first head and neck cancer treated with Cesium-131. Dwight Babcock, IsoRay’s CEO, stated “This is an important development in our strategy to significantly broaden our base beyond prostate cancer. Cesium-131 has unique characteristics for treating many additional cancers such as this new application that provided a minimally invasive treatment option for this patient.”
Update 8/19/09: IsoRay received FDA clearance to market Cesium-131 for treating other cancers — such as those affecting the head, neck and other organs — beyond the current prostate market.
Related external links (will open a new window):
IsoRay – Richland, Wash. – July 27, 2009
IsoRay – Richland, Wash. – August 18, 2009
Related WTC links:
– end of post –